Focused On The Cure
The first company in Iran to have developed CAR-T CELL therapy.
WHO WE ARE?
At CARA Yakhteh, we advance autologous CAR T-cell therapy through cutting-edge cellular engineering. Our focus is on developing precise, patient-specific cancer treatments that drive the next era of targeted immunotherapy.
OUR TECHNOLOGY
At CARA Yakhteh, our technology platform is built around the precise engineering of autologous T cells to create highly targeted
CAR T-cell therapies for hematologic malignancies.
We combine advanced molecular biology, cell processing, and immunogenetics to deliver therapies that are personalized, potent, and scalable.
Antigen-Specific CAR Design
Optimized T Cell Activation & Expansion
Precision Genetic Modification
Advanced Formulation & Cryopreservation
Integrated Manufacturing Workflow
OUR PRODUCTS
CAR-T CELL THERAPY
Human T-CELL suspension genetically modified for autologous use only.
THE NEWS
CARAYAKHTEH NEWS
CAR-T Therapy- Pipeline Insight, 2023
This news refers to a comprehensive report on the current status and future of CAR-T cell therapy. “Pipeline Insight” typically refers to the collection of projects, drugs, or therapies that are in various stages of research, development, and clinical trials. This report likely includes an analysis of market trends, active companies, types of CAR-T therapies under development, and future projections.
New Advancements in CAR-T Cell Therapy in an Article from Nature Reviews Drug Discovery
This article, published in the prestigious journal Nature Reviews Drug Discovery, focuses on “In vivo chimeric antigen receptor (CAR)-T cell therapy.” In vivo CAR-T therapy refers to an approach where the necessary genes for constructing the CAR are delivered directly into the patient’s T cells within their body, as opposed to the cells being removed, engineered, and then reinfused (known as “ex vivo” therapy). This method holds the potential to simplify the treatment process and reduce costs.
Significant Growth Predicted for the CAR-T Cell Therapy Market by 2034
This news is based on a market analysis report that forecasts a substantial increase in the global market value of CAR-T cell therapy. Such predictions are usually made based on investment levels, the number of clinical trials, new drug approvals, and the therapeutic potential of these methods for various diseases (especially cance
Challenges and Future Directions of CAR-T Cell Therapy in a Scientific Article
This article, published in Signal Transduction and Targeted Therapy, analytically examines the obstacles and issues currently facing CAR-T cell therapy. These challenges might include side effects, high costs, limited efficacy for all patients or cancer types, and manufacturing complexities. Furthermore, the article discusses future research trends and potential solutions being considered to overcome these challenges.